DeCure for Growth Hormone-Producing Pituitary Gland Adenoma
DeCure's autonomous Metabolic AI scientist is researching a drug-repurposing hypothesis for Growth Hormone-Producing Pituitary Gland Adenoma — screening already-approved drugs against its 9-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleGrowth Hormone-Producing Pituitary Gland Adenoma maps to a 9-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for growth hormone-producing pituitary gland adenoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
protein kinase cAMP-dependent type I regulatory subunit alpha (PRKAR1A) — PRKAR1A is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet pcgdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5KJZ · 1.347 Å · ligand CYCLIC GUANOSINE MONOPHOSPHATE (PCG). Experimental structure, not a prediction.
What the evidence adds up to
A 2016 review states that acromegaly treatment is an evolving field where understanding of molecular targets and drug therapies has improved treatment options for patients with excess growth hormone levels, and that this may represent a paradigm shift for the future of pituitary adenoma treatment. The same review notes that current treatment requires a balance of conservative management, surgical resection, and in select tumour types, molecular therapy. A 2001 review of pituitary tumorigenesis reports that overexpression of growth factors and their receptors, such as EGF, TGFalpha, EGF-R and VEGF, has been identified in pituitary adenomas, and that aberrant expression of members of the FGF family, an FGF antisense gene and FGF receptors have all been described. That review also states that most pituitary tumours are not associated with underlying hyperplasia, and that the evidence suggests various hypophysiotropic hormones and growth factors likely play a role as promoters of tumour cell growth in genetically transformed cells.
A 2015 case report describes a 37-year-old woman with a growth hormone-producing pituitary adenoma with lymphocytic infiltration and brain parenchyma invasion. Her laboratory studies showed markedly elevated levels of insulin-like growth factor 1 (IGF-1) and low levels of follicle stimulating hormone and luteinising hormone. The tumour was completely excised via a trans-nasal endoscopic approach, and serum IGF1 levels gradually decreased to the normal range. The patient was symptom free for three and a half years before returning with visual impairment; brain MRI then showed a supra-sellar mass growing independently into the remaining sellar part. A second surgical operation was performed, and histopathological and immunohistochemistry examination revealed a rare case of growth hormone producing pituitary adenoma with brain invasion and lymphocytic infiltration.
No controlled trial data are provided in these abstracts. The 2016 review does not name any specific molecular therapy, report response rates, or give survival numbers. The 2001 review does not test a drug. The 2015 case report describes one patient who relapsed after surgery, but no drug was used beyond surgical resection.
What is still missing is any prospective clinical trial testing a repurposed drug in growth hormone-producing pituitary adenoma, with defined endpoints such as biochemical control or tumour shrinkage. No patient stratification by molecular markers has been validated in a trial setting, and no funding for such a trial is described in these abstracts.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Brain Pathology · 2001 · 60 citations · open access
The Role of Hormones, Growth Factors and Their Receptors in Pituitary Tumorigenesis
AbstractNumerous factors have been shown to govern adenohypophysial cell proliferation. Human and animal models have documented that the hypothalamic trophic hormone growth hormone-releasing hormone stimulates cell proliferation, and prolonged stimulation leads to tumor formation. Similarly, lack of dopaminergic inhibition of lactotrophs and lack of feedback suppression by adrenal, gonadal or thyroid hormones are implicated, perhaps through hypothalamic stimulatory mechanisms, in pituitary adenoma formation superimposed on hyperplasia. However, most pituitary tumors are not associated with underlying hyperplasia. Overexpression of growth factors and their receptors, such as EGF, TGFalpha, EGF-R and VEGF has been identified in pituitary adenomas, and reduction of follistatin expression has been implicated in gonadotroph adenomas. Aberrant expression of members of the FGF family, an FGF antisense gene and FGF receptors have all been described in pituitary adenomas. The clonal composition of pituitary adenomas attests to the molecular basis of pituitary tumorigenesis, however, the evidence suggests that these various hypophysiotropic hormones and growth factors likely play a role as promoters of tumor cell growth in genetically transformed cells.
Frontiers in Surgery · 2016 · 6 citations · open access
Advancing Treatment of Pituitary Adenomas through Targeted Molecular Therapies: The Acromegaly and Cushing Disease Paradigms
AbstractThe current treatment of pituitary adenomas requires a balance of conservative management, surgical resection, and in select tumor types, molecular therapy. Acromegaly treatment is an evolving field where our understanding of molecular targets and drug therapies has improved treatment options for patients with excess growth hormone levels. We highlight the use of molecular therapies in this disease process and advances in this field, which may represent a paradigm shift for the future of pituitary adenoma treatment.
Iranian Journal of Cancer Prevention · 2015 · 5 citations · open access
Invasive Growth Hormone Producing Pituitary Adenoma With Lymphocytic Infiltration: A Case Report and Literature Review
AbstractINTRODUCTION: We have presented a rare case of growth hormone (GH) producing pituitary adenoma with lymphocytic infiltration and brain parenchyma invasion. CASE PRESENTATION: A 37-year-old woman has presented with complaints of headache, amenorrhea and acromegalic features. Her laboratory studies showed markedly elevated levels of Insulin-like Growth Factor 1 (IGF-1), and low levels of follicle stimulating hormone and luteinizing hormone. Computerized tomography has revealed a pituitary mass without extra-sellar extension. The tumor has completely excised via trans-nasal endoscopic approach. Histologically, the tumor has diagnosed as a pituitary adenoma with GH positive cells. The serum IGF1 levels have gradually decreased to the normal range and the patient was symptom free for three and a half years when she has returned with complaint of visual impairment. The brain MRI that time has shown a supra-sellar mass growing independently into the remaining sellar part. Subsequently, surgical operation has performed via trans-nasal endoscopic approach. Histopathological and immunohistochemistry examination have revealed a rare case of growth hormone producing pituitary adenoma with brain invasion and lymphocytic infiltration. CONCLUSIONS: The aim of this publication was to present a rare case of growth hormone producing pituitary adenoma with brain invasion and lymphocytic infiltration.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
